There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Roivant Sciences (ROIV – Research Report), Terns Pharmaceuticals (TERN – Research Report) and Altimmune (ALT – Research Report) with bullish sentiments.
Roivant Sciences (ROIV)
In a report released today, Dennis Ding from Jefferies maintained a Buy rating on Roivant Sciences, with a price target of $16.00. The company’s shares closed last Tuesday at $10.92.
According to TipRanks.com, Ding is a 4-star analyst with an average return of
Roivant Sciences has an analyst consensus of Strong Buy, with a price target consensus of $16.88, which is a 54.4% upside from current levels. In a report released today, Deutsche Bank also maintained a Buy rating on the stock with a $15.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals received a Buy rating and a $22.00 price target from Jefferies analyst Akash Tewari today. The company’s shares closed last Tuesday at $6.64.
According to TipRanks.com, Tewari is a 5-star analyst with an average return of
Currently, the analyst consensus on Terns Pharmaceuticals is a Strong Buy with an average price target of $14.92, representing an 113.1% upside. In a report issued on March 27, UBS also maintained a Buy rating on the stock with a $18.00 price target.
Altimmune (ALT)
In a report released today, Roger Song from Jefferies maintained a Buy rating on Altimmune, with a price target of $35.00. The company’s shares closed last Tuesday at $9.36.
According to TipRanks.com, Song is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Altimmune with a $23.40 average price target, which is a 136.4% upside from current levels. In a report issued on March 27, Piper Sandler also maintained a Buy rating on the stock with a $25.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ROIV:
- Roivant Sciences board approves of repurchase program up to $1.5B
- Roivant Sciences announces NEPTUNE study met primary efficacy endpoint
- Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
- Roivant Sciences to replace Sunrun in the S&P 400 at open on 4/1
- Sunrun to replace PGT Innovations in the S&P 600 at open on 4/1